NASDAQ: SABS - SAB Biotherapeutics, Inc.

Rentabilidade por seis meses: -40.37%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção SAB Biotherapeutics, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

mais detalhes
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2021-02-09
ISIN US78397T1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sabbiotherapeutics.com
Цена ао 1.63
Alteração de preço por dia: -1.23% (1.63)
Alteração de preço por semana: -0.6173% (1.62)
Alteração de preço por mês: -5.85% (1.71)
Alteração de preço em 3 meses: -60.54% (4.08)
Mudança de preço em seis meses: -40.37% (2.7)
Mudança de preço por ano: -70.83% (5.52)
Mudança de preço em 3 anos: -24.77% (2.14)
Mudança de preço em 5 anos: 0% (1.61)
Mudança de preço em 10 anos: 0% (1.61)
Mudança de preço desde o início do ano: -65.38% (4.65)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 1.75 8
P/BV 0.0684 10
P/E 0 0
EV/EBITDA 1.36 10
Total: 6

Eficiência

Nome Significado Nota
ROA, % -50.27 0
ROE, % -73.64 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.1721 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -34.15 0
Rentabilidade Ebitda, % 365.04 10
Rentabilidade EPS, % 3428.04 10
Total: 8
Mais detalhes

Instituições Volume Compartilhar, %
Marshall Wace LLP 4585282 49.7
RA Capital Management, L.P. 2374081 25.73
COMMODORE CAPITAL LP 1831746 19.86
RTW Investments LP 917828 9.95
BVF Inc. 917828 9.95
Sessa Capital IM, L.P. 458457 4.97
Vanguard Group Inc 99614 1.08
First Premier Bank 80754 0.88
Pathstone Holdings, LLC 50651 0.55
Geode Capital Management, LLC 35636 0.39

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
iShares Micro-Cap ETF 0.00541 17.09 1.54048
0.0117.091.54



Supervisor Cargo Pagamento Ano de nascimento
Mr. Samuel J. Reich CEO & Executive Chairman 363.2k 1975 (50 anos)
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 402.56k 1966 (59 anos)
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 25k 1956 (69 anos)
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 774.45k 1973 (52 ano)
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer N/A
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 443.2k 1971 (54 ano)
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Mark W. Conley Interim Chief Financial Officer

Endereço: United States, Sioux Falls. SD, 2100 East 54th Street North - abrir no Google Maps, abrir mapas Yandex
Site: https://www.sabbiotherapeutics.com